Pugatch Consilium managing director, Meir Perez Pugatch, says that IP has been the “bridge” in the various biopharma R&D collaborations that have helped deliver unprecedented results during the pandemic. He also weighs in on the divisive proposal of waiver of intellectual property rights for vaccines, treatments and diagnostics relating to COVID-19.
Issues around enforcing biopharma intellectual property rights (IPR) may be sensitive amid COVID-19, with strong views at both ends of the spectrum. But the pandemic has actually shown that the IPR-based system is working, one expert has argued.
At a media program organized by MSD. (as Merck & Co., Inc. is known outside North America), Dr...